Jing-Yuan Liu
Toledo Clinic Cancer Center(US)University of Toledo(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, HIV/AIDS drug development and treatment, Drug Transport and Resistance Mechanisms, PARP inhibition in cancer therapy, Cancer, Lipids, and Metabolism
Most-Cited Works
- → Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?(2018)137 cited
- → A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion(2014)119 cited
- → FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1(2016)91 cited
- → Targeting survivin for therapeutic discovery: past, present, and future promises(2017)87 cited
- → Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors(2016)80 cited
- → Repositioning Proton Pump Inhibitors as Anticancer Drugs by Targeting the Thioesterase Domain of Human Fatty Acid Synthase(2014)76 cited
- → Identification of Novel Small Molecule Inhibitors of the XPA Protein Using in Silico Based Screening(2010)38 cited
- → Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase(2014)27 cited
- → Critical Residue That Promotes Protein Dimerization: A Story of Partially Exposed Phe25 in 14-3-3σ(2011)22 cited
- → Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth(2018)20 cited